载药微球经动脉化疗栓塞对比碘油栓塞治疗中晚期肝癌的有效性及安全性分析

doi:10.3969/j.issn.1006-6233.2023.12.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1241 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the application value of drug-eluting microsphere transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) in intermediate to advanced hepatocellular carcinoma. Methods: A retrospective analysis was conducted on patients with intermediate to advanced hepatocellular carcinoma in our hospital from March 2018 to March 2021. The patients were grouped according to the treatment method, with 92 cases undergoing DEB-TACE (included in the DEB-TACE group) and 125 cases undergoing cTACE (included in the cTACE group). The efficacy and safety of the two groups were compared. Results: The disease remission rate in the DEB-TACE group was higher than that in the cTACE group at 1 month after surgery. The differences in TBIL, ALT, AST, and AFP before and after surgery were greater in the DEB-TACE group than in the cTACE group. The severity of postoperative vomiting was lower in the DEB-TACE group than in the cTACE group. The one-year survival rate was higher in the DEB-TACE group than in the cTACE group (P<0.05). Conclusion: DEB-TACE treatment is more effective for intermediate to advanced hepatocellular carcinoma, with fewer complications and higher safety.

Key words： Drug-eluting beads transarterial chemoembolization Transcatheter arterial chemoembolization Liver cancer Middle-to-advanced stage

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.12.021 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I12/2049

[1] 王砚亮,宋威,卞益同,等.CalliSpheres载药微球与常规TACE在治疗原发性肝癌中的临床疗效及安全性对比[J].临床放射学杂志,2020,11(9):1853-1859.
[2] 蒋成胜,俞广进,熊奇如.DEB-TACE与cTACE治疗不可切除肝细胞性肝癌的疗效与安全性对比:系统综述与荟萃分析[J].肝胆外科杂志,2020,28(1):17-21.
[3] 曹国洪,王凯,李佳琪,等.CalliSpheres^(R)载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J].中国介入影像与治疗学,2018,15(1):42-46.
[4] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].肿瘤,2009,029(4):295-304.
[5] Robertson D M,Cahir N,Burger H G,et al.Inhibin forms in serum from postmenopausal women with ovarian cancers[J].Clinical Endocrinology,2010,50(3):381-386.
[6] Wilcken D,Gupta V J.Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide[J].European Journal of Clinical Investigation,2010,9(4):301-307.
[7] 曹耿飞,张海潇,顾俊鹏,等.载药微球栓塞联合索拉非尼治疗不可切除肝癌安全性和疗效[J].中华肝脏外科手术学电子杂志,2021,10(1):255-259.
[8] 王忠,刘启榆,杨伟,等.国产CalliSpheres载药微球DEB-TACE治疗无法手术肝癌的临床价值[J].肝脏,2019,24(7):767-770.
[9] 蔡争,宋建涛,甄文瑞,等.MRI扩散加权成像联合外周血CD4⁺/CD8⁺比值预测CalliSpheres载药微球栓塞介入治疗晚期肝癌疗效的价值[J].放射学实践,2023,38(1):84-88.
[10] Lee I J,Lee J H,Yun B L,et al.Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients[J].Therapeutic Advances in Medical Oncology,2019,11(14):224-228.
[11] Andreozzi G,Lorenzoni V,Bargellini I,et al.PCN93 cost-effectiveness analysis of DEB-TACE compared to lipiodol-TACE as first LINE treatment for unresectable HCC - science direct[J].Value in Health,2020,23(11):279-282.